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Necker-Enfants Malades, Paris, FranceRecent research on podocytes has proposed B7-1 as an
important player in podocyte biology and as a potential
new therapeutic target. B7-1 was upregulated in injured
podocytes and described as a biomarker to identify
patients who may beneﬁt from abatacept, a B7-1 blocker.
However, after this initial enthusiasm, several reports have
not conﬁrmed the efﬁciency of abatacept at inducing
proteinuria remission in patients. In order to resolve these
discrepancies, we explored the role of B7-1 in the injured
podocyte. Both primary cultured and immortalized
podocytes were exposed to lipopolysaccharides, but
this failed to induce B7-1 expression at the mRNA and
protein levels. Importantly, TLR-4 engagement conﬁrmed
lipopolysaccharide efﬁcacy. We then evaluated B7-1
expression in several mouse models of podocyte injury
including treatment with lipopolysaccharide or Adriamycin,
a lupus pronemodel (NZB/W F1) and subtotal nephrectomy.
Using 3 commercially available anti-B7-1 antibodies and
appropriate controls, we could not ﬁnd B7-1 expression in
podocytes, whereas some inﬁltrating cells were positive.
Thus, our ﬁndings do not support a role for B7-1 in podocyte
biology. Hence, further studies are mandatory before
treating proteinuric patients with B7-1 blockers.
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Kidney International (2016) 90, 1037–1044T he renal glomerulus functions as a barrier betweenblood and urinary spaces. It permits the passage ofsmall molecules and water freely into the urine while
preventing the loss of large serum proteins such as albu-
min. The barrier is composed of podocytes and fenestrated
endothelial cells separated by the glomerular basement
membrane. Podocytes are differentiated cells that function
as vasculature-supporting cells producing basement mem-
brane and vascular growth factors.1 Podocyte injuries
lead to protein redistribution in the slit diaphragm, the
loss of nephrin and podocin, and the effacement of the
foot processes.2 Foot process effacement represents a
reversible step that becomes irreversible if the injury is sus-
tained. The failure of repair mechanisms promotes podo-
cyte detachment, apoptosis, podocyte depletion, and the
development of focal and segmental glomerulosclerosis
(FSGS).3
Recently, B7-1, a costimulatory receptor on antigen pre-
senting cells, was found to be induced in podocytes during
injury.4 B7-1 engagement in vitro seems to lead to cyto-
skeleton modiﬁcation through b1 integrin.4 In vivo, podo-
cyte B7-1 recruitment seems to participate to foot process
effacement and proteinuria occurrence in a variety of con-
ditions, including activation of innate immune signaling via
Toll-like receptor 4 (TLR-4) by bacterial endotoxin (LPS).4
In humans, B7-1 was upregulated in several proteinuric
states, including FSGS.4,5 Indeed, B7-1 expression in
podocytes was proposed as both a biomarker that can
identify proteinuric patients who might beneﬁt from treat-
ment with abatacept, a B7-1 blocker,6 and as a new thera-
peutic target.5 These ﬁndings recently led to the use of
abatacept in the treatment of 4 patients with a resistant form
of recurrent FSGS after transplantation.5 This treatment
pushed patients into remission with only 1 or 2 abatacept
infusions.5
However, although this ﬁrst report was exciting, further
work has not conﬁrmed the beneﬁcial effect observed with
abatacept at inducing FSGS remission after transplantation.7,8
Furthermore, B7-1 immunostaining on kidney biopsies has
been largely controversial,9,10 leading to the hypothetical theory
of epitope instability.11
To understand these discrepancies, we decided to explore
B7-1 expression inmouse podocytes using several injurymodels
and in cultured podocytes.1037
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Figure 1 | B7-1 is not induced in primary cultured podocytes after injury. (a) Coimmunostaining for nephrin (green), nestin (red), and
podocin (purple) in mouse podocytes isolated from primary culture. (b) B7-1 mRNA is barely detectable in podocytes at baseline (Continued)
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B7-1 is not induced in cultured podocytes after injury
We ﬁrst decided to investigate B7-1 expression in vitro.
Toward this aim, we isolated mouse podocytes. We conﬁrmed
that after 14 days in culture, the podocytes were still in a
differentiated state with suggestive podocyte morphology and
that they expressed typical podocyte markers, such as neph-
rin, podocin, and nestin (Figure 1a). Then, we exposed the
podocytes to LPS, a molecule reported to induce B7-1 mRNA
expression in podocytes.4,5 At baseline, we observed a very
small amount of B7-1 mRNA in our primary culture of
podocytes. After LPS treatment, we did not see B7-1 mRNA
induction (Figure 1b), whereas we could detect IL-6 and
IL-1b mRNA induction conﬁrming TLR-4 engagement in
primary cultured cells (Figure 1b). Next, we explored whether
B7-1 was detectable at the protein level in our differentiated
podocytes. AWestern blot analysis revealed that B7-1 was not
present at the protein level in podocytes, neither at baseline
nor after LPS treatment (Figure 1c). The costaining experi-
ments did not conﬁrm B7-1 expression in primary culture of
podocytes either at baseline or after LPS treatment
(Figure 1d). To ensure that the anti-B7-1 antibody was able to
detect the murine form of B7-1, we transfected HeLa cells
with a vector encoding mouse B7-1 cDNA as positive con-
trols. Additionally, we tested 2 other anti-B7-1 antibodies that
were commercially available. We conﬁrmed that the anti-
bodies were able to detect the B7-1 protein in HeLa trans-
fected cells (Figure 1e) but failed to detect B7-1 in podocytes
exposed either to vehicle or LPS.
Because a primary culture of glomerular cells contain
podocytes but also a few endothelial and mesangial cells, we
explored B7-1 expression in immortalized mouse podocytes.12
At baseline, we observed a very small amount of B7-1mRNA in
cultured podocytes, but we did not detect B7-1 mRNA in-
duction (Figure 2a) or B7-1 protein after LPS treatment
(Figure 2b). IL-6 mRNA induction was detected, conﬁrming
TLR-4 engagement in podocytes (Figure 2a). Costaining ex-
periments using 3 commercially available anti-B7-1 antibodies
conﬁrmed the absence of B7-1 expression in immortalized
mouse podocytes at baseline or after LPS treatment (Figure 2c).
Indeed, in our hands, we did not conﬁrm B7-1 expression
in stressed podocytes.
B7-1 is not induced in mouse models of podocyte injuries
B7-1 has been upregulated in several mouse models of
proteinuria.4 We next investigated B7-1 expression in different
mouse models of podocyte injury, including LPS, AdriamycinFigure 1 | (Continued) and is not induced after lipopolysaccharide (LPS
engagement after LPS treatment. (c) Western blot of B7-1 (SC-9091 from
cultures of mouse podocytes exposed to either vehicle or 50.0 mg/ml LPS
containing mouse B7-1 DNA. Western blot of podocin (upper band) conﬁ
B7-1 (red, SC-9091 from Santa Cruz Biotechnology Inc.), and podocin (p
(upper panel) or 50.0 mg/ml LPS (lower panel). (e) B7-1 immunostaining
R&D Systems; and H-208: SC-9091 from Santa Cruz Biotechnology Inc.) i
vector or mouse B7-1 DNA. Bar ¼ 10 mm. The data are represented as th
podocytes treated with vehicle versus LPS: *** P < 0.001. DAPI, 40,6-diam
Kidney International (2016) 90, 1037–1044(Sigma Aldrich, St. Quentin Fallavier, France) nephropathy,
lupus prone mice (NZB/W F1), and subtotal nephrectomy.
We ﬁrst validated that the LPS (200 mg), Adriamycin, lupus
prone mouse, and nephrectomy models produced albumin-
uria (Figure 3a). As expected, almost all the models lead to
albuminuria. However, LPS-treated mice showed only minor
albuminuria induction. We decided to test 2 additional dos-
ages of LPS (300 and 400 mg) and failed to induce more
proteinuria. Using 300 and 400 mg, the mice died within 24
hours of injection due to sepsis shock condition (not shown).
Next, we performed a morphological analysis of the kidney
sections in each condition. Histological analyses revealed that
glomeruli appeared grossly normal in LPS-injected mice,
whereas glomeruli were severely injured in mice injected with
Adriamycin, in lupus prone mice, and after nephrectomy
(Figure 3b). However, electron microscopy revealed that LPS
induced foot process effacement with cytoskeleton reorgani-
zation (Figure 3c). We then performed colocalization studies
in parafﬁn-embedded kidneys between nestin, a podocyte
marker, and B7-1 in all models of injuries. The colocalization
studies were performed with the 3 commercially available
B7-1 antibodies. Careful examination of glomeruli showed
that B7-1 was not detectable in podocytes (Figure 3d).
Importantly, we could detect B7-1 expression in some inﬁl-
trating cells, conﬁrming that anti-B7-1 antibodies were efﬁ-
cient in detecting the B7-1 epitope in our sections. Lastly, we
performed costaining between anti-B7-1 antibody and nestin
on frozen kidney sections. Similarly, using the 3 commercially
available anti-B7-1 antibodies, we could not ﬁnd B7-1
expression in podocytes, whereas we could ﬁnd B7-1
expression in some inﬁltrating cells (Figure 3e). Of note,
because the anti-B7-1 antibodies gave similar results, only
the AF140, goat antibody from R&D Systems Europe (Lille,
France) is shown in Figure 3e. We therefore conclude that
B7-1 is not detectable in these proteinuric mouse models.
DISCUSSION
In this study, we did not observe B7-1 expression in mouse
podocytes at the protein level at baseline or after injury. We
could detect only a very small amount of mRNA, which did
not increase after LPS stimulation, a condition that was re-
ported to induce its expression.4 Our in vivo data using
several mouse models of proteinuric diseases corroborate our
in vitro ﬁndings. Importantly, our experimental ﬁndings are
in line with accumulating evidence from independent groups
showing that B7-1 blockers are not associated with albu-
minuria improvement in patients.7,8,13) stimulation. IL-6 and IL-1b mRNA conﬁrmed Toll-like receptor 4
Santa Cruz Biotechnology Inc., Heidelberg, Germany) in primary
for 24 hours. Cþ: positive control, HeLa cells transfected with a vector
rms podocyte enrichment. (d) Coimmunostaining for nephrin (green),
urple) in mouse podocytes 24 hours after exposure to either vehicle
using 3 anti-B7-1 antibodies (2A2: ab86473 from Abcam; AF140: from
n HeLa cells transfected with plasmids containing either an empty
e means  SEM. Analysis of variance followed by a Tukey-Kramer test;
idino-2-phenylindole.
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Figure 2 | B7-1 is not induced in immortalized podocytes after injury. (a) B7-1 mRNA is barely detectable in immortalized podocytes
at baseline and is not induced after lipopolysaccharide (LPS) stimulation. IL-6 mRNA conﬁrmed Toll-like receptor 4 engagement (Continued)
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observed in injured podocytes.4 Indeed, it was shown that
injured podocytes expressed B7-1 leading to cytoskeletal
modiﬁcation in vitro. Furthermore, these in vitro ﬁndings
were also observed in several models of proteinuria including
activation of innate immune signaling via TLR-4 by bacterial
endotoxin (LPS).4 More strikingly, mice with severe com-
bined immunodeﬁciency who were exposed to LPS rapidly
upregulate B7-1 in podocytes and develop proteinuria,
whereas mice lacking B7-1 were protected from LPS-induced
nephrotic syndrome, suggesting a link between podocyte B7-1
expression and proteinuria.4 Importantly, the mice used in
the study were knockouts for B7-1/ but not for podocyte-
speciﬁc B7-1 knockouts, meaning that the beneﬁcial effect
that was observed could be related to an effect on immune
cells rather than a direct effect on podocytes. Yu et al.5 then
reported the successful treatment of 4 patients with recurrent
FSGS on the allografted kidney using a B7-1 blocker. However,
others did not conﬁrm these clinical results,7,8,13 and B7-1
expression in podocytes in vivo has been controversial.14,15
Using appropriate controls, we could not conﬁrm that
B7-1 is expressed at the protein level or induced at the mRNA
level in injured murine podocytes. We observed that LPS
engaged the TLR-4 pathway in podocytes as assessed by the
mRNA induction of IL-6 and IL-1b but did not induce B7-1
expression. These results were obtained in primary cultured
podocytes and then conﬁrmed in immortalized podocytes.
We also failed to detect B7-1 in different mouse models of
proteinuria. In all these models, we could not detect B7-1
expression in podocytes. Importantly, we could detect inﬁl-
trating cells stained for B7-1, an internal control of the val-
idity of the different antibodies used. All sample kidneys were
ﬁxed, processed in the same way, and stained in the same time
to avoid any bias.
We must be cautious in the interpretation of the results. In
fact, it is possible that in human kidney diseases, B7-1 plays a
role in podocytes, a condition that was not explored here.
Additionally, abatacept was efﬁcient at inducing proteinuria
remission in a few patients.5 However, it is possible that the
effect that was observed with abatacept in FSGS patients was
not directly related to a podocyte effect but rather, was due to
an action on immune cells or an off-target effect of the drug.
Many reports did not observe such an effect of abatacept on
proteinuria in recurrent FSGS after transplantation, but we
know that the disease is extremely heterogeneous, and not all
patients will beneﬁt from abatacept treatment. The identiﬁ-
cation of such responders will remain an important challenge.
In conclusion, using the appropriate tools, we did not
conﬁrm that B7-1 was expressed in murine podocytes under
pathological conditions, and further studies are recommendedFigure 2 | (Continued) after LPS treatment. (b) Western blot of B7-1 (SC
exposed to either vehicle or 50.0 mg/ml LPS for 24 hours. Cþ: positive con
(c) Coimmunostaining for nestin (red), nephrin (green), and 3 different a
AF140: from R&D Systems [Lille, France]; and H-208: SC-9091 from Santa
exposure to either vehicle (upper panel) or 50.0 mg/ml LPS (lower panel).
of variance followed by a Tukey-Kramer test; podocytes treated with ve
Kidney International (2016) 90, 1037–1044before using B7-1 blockers in patients with proteinuric
diseases.
MATERIALS AND METHODS
Animal experiments
The mouse strains that were used in these studies included FVB/N,
C57BL/6, and BALB/c (Charles River Laboratories, Wilmington,
MA). The animals were fed ad libitum and housed at a constant
ambient temperature under a 12-hour light cycle. All animal pro-
cedures were approved by the Departmental Director of “Services
Vétérinaires de la Préfecture de Police de Paris” and by the ethical
committee of Paris Descartes University. Several groups of mice were
investigated in complementary studies.
Lipopolysaccharide injections. Eight-week-old male C57BL/6
mice were i.p. administered either 200 mg of lipopolysaccharide
(Ultrapure LPS; 1 mg/ml in sterile LPS-free phosphate-buffered sa-
line, n ¼ 6) in a total volume of 200 ml or an equal volume of sterile
LPS-free phosphate-buffered saline (n ¼ 6) (Ultrapure LPS from
E. coli O111:B4, InvivoGen, Toulouse, France). Urine samples were
collected and analyzed 24 hours post injection and immediately prior
to sacriﬁce. Kidneys and spleens were then removed for morpho-
logical and protein studies.
Adriamycin nephropathy. Eight-week-old male BALB/c
mice (n ¼ 12) were administered either 17 mg/g body weight
Adriamycin (Sigma Aldrich) diluted in 0.9% saline or an equal
volume of 0.9% saline (n ¼ 12) into the retrobulbar plexus. Twenty-
four hours before sacriﬁce, urine was collected for determination
of proteinuria. The mice were sacriﬁced 7 days after injection,
and their kidneys were removed for morphological and protein
studies.
Subtotal nephrectomy. Eight-week-old female FVB/N mice
were subjected to 75% nephrectomies (n ¼ 10) or sham-operations
(n ¼ 10) and were sacriﬁced 2 months after surgery. The subtotal
nephrectomies were performed as previously described.3 After sur-
gery, the mice were fed a deﬁned diet containing 30% casein and
0.5% sodium. Twenty-four hours before sacriﬁce, urine samples
were collected for determination of proteinuria. At the time of sac-
riﬁce, kidneys were removed for morphological and protein studies.
NZB/W F1. Forty-six-week-old mice (n ¼ 6) from Jackson
Laboratories (Bar Harbor, ME) were used as a model of lupus
nephritis. Twenty-four hours before they were killed, urine samples
were collected for determination of proteinuria. At the time they
were killed, their kidneys were removed for morphological and
protein studies.
Urine analyses
For urine samples, albumin and creatinine concentrations were
measured using an Olympus multiparametric analyzer (Instrumen-
tation Laboratory, Bedford, MA).
Morphological analysis
Mouse kidneys were ﬁxed in 4% paraformaldehyde and embedded
with parafﬁn, and 4-mm sections were stained withMasson trichrome.-9091 from Santa Cruz Biotechnology Inc.) in immortalized podocytes
trol, HeLa cells transfected with a vector containing mouse B7-1 DNA.
nti-B7-1 antibodies (purple, 2A2: ab86473 from Abcam [Paris, France];
Cruz Biotechnology Inc.) in immortalized podocytes 24 hours after
Bar ¼ 10 mm. The data are represented as the means  SEM. Analysis
hicle versus LPS: *** P < 0.001. DAPI, 40,6-diamidino-2-phenylindole.
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Figure 3 | B7-1 is not induced in murine models of podocyte injury. (a) The albumin-creatinine ratio in the different models of podocytes
injuries. (b) Glomerular morphology in sham-operated mice, in mice injected with lipopolysaccharide (LPS) (day 1 post injection), (Continued)
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described.16
Immunoﬂuorescence
Four-micrometer, parafﬁn-embedded sections were incubated with
3 different anti-B7-1 antibodies: (i) anti-B7-1 antibody from
Santa Cruz Biotechnology Inc. (Heidelberg, Germany; (ii) anti-B7-1
antibody (mouse, 2A2) from Abcam (Paris, France); (iii) anti-B7-1
antibody (AF140, goat) from R&D Systems Europe. We also used
anti-Nephrin (Progen Biotechnik GmbH, Heidelberg, Deutsch-
land), anti-Podocin (H208, rabbit; Sigma Aldrich), and anti-Nestin
(Rat-401; Developmental Studies Hybridoma Bank, University
of Iowa, Iowa City, IA) antibodies after appropriate antigen
retrieval. The sections were deparafﬁnized and rehydrated, then
the slides were brought to boil in Tris–ethylenediamine tetraacetic
acid buffer (10 mM Tris base, 1 mM ethylenediamine tetraacetic
acid solution, 0.05% Tween 20, pH 9.0) and maintained at a sub-
boiling temperature (95 C) for 40 minutes. This step was followed
by cooling time on the bench for 30 minutes. Then, each section
was blocked with Tris-buffered saline Tween-20/5% normal goat
serum for 30 minutes. Anti-B7-1 antibodies were used at a
dilution of 1:50 and incubated on the sections overnight at 4 C.
The primary antibodies were revealed with the appropriate Alexa
488-, 555-, or 647-conjugated secondary antibodies (Molecular
Probes, San Diego, CA) used at a dilution of 1:200 for 2 hours at
room temperature. Immunoﬂuorescence staining was visualized
using a Zeiss LSM 700 confocal microscope (Jena, Germany). For
each sample, we evaluated all glomeruli per section (a minimum of
50 glomeruli, 2 to 4 sections per mouse, were evaluated per
animal).
Kidneys frozen in optimal cutting temperature compound were
cut in 4-mm sections, ﬁxed in acetone, and then incubated with the
anti-B7-1 antibody from Santa Cruz Biotechnology the anti-B7-1
antibody (mouse, 2A2) from Abcam, or the anti-B7-1 antibody
(AF140, goat) from R&D Systems Europe, and anti-Nestin (Rat-401,
Developmental Studies Hybridoma Bank) antibodies.
Cell culture and cell experiments
Primary podocyte cell culture. Mouse podocytes were isolated
and cultured as previously described.17 Brieﬂy, primary cultures of
podocytes were maintained in Roswell Park Memorial Institute 1640
medium supplemented with 10% fetal calf serum, 100 U/ml peni-
cillin, 100 mg/ml streptomycin, and insulin-transferrin-sodium
selenite media (Sigma Aldrich) for 14 days. For LPS experiments,
the cells were treated with 50 mg/ml of Ultrapure E. coli (LPS from
E. coli O111:B4; InvivoGen) for 24 hours before performing
immunoﬂuorescence, quantitative polymerase chain reaction, and a
Western blot analysis. Each experiment was performed in triplicate
and repeated $3 times.
Immortalized podocyte cell culture. Mouse immortalized
podocytes were cultured as previously described.18 Brieﬂy, cells were
maintained in Roswell Park Memorial Institute 1640 medium
supplemented with 10% fetal calf serum, 100 U/ml penicillin, andFigure 3 | (Continued) in mice injected with Adriamycin (day 7 post inje
nephrectomy (Nx). (c) Transmission electron microscopy of the glomeru
day after injection. Bar ¼ 0.5 mm. (d) Coimmunostaining for nestin (green
AF140: from R&D Systems; and H-208: SC-9091 from Santa Cruz Biotechno
injuries. (e) Coimmunostaining for nestin (green) and anti-B7-1 antibody
models of podocyte injuries. Bar ¼ 10 mm. Analysis of variance followed
40,6-diamidino-2-phenylindole.
Kidney International (2016) 90, 1037–1044100 mg/ml streptomycin. To propagate podocytes, cells were culti-
vated at 33 C on type I collagen (permissive conditions) in culture
medium supplemented with 10 UI/ml recombinant interferon-g. To
induce differentiation, podocytes were maintained on type I collagen
at 37 C without supplementation with interferon-g (nonpermissive
conditions). For LPS experiments, the cells were treated with
50 mg/ml of Ultrapure E. coli (LPS from E. coli O111:B4, InvivoGen)
for 24 hours before performing immunoﬂuorescence, quantitative
polymerase chain reaction, and a Western blot analysis. Each
experiment was performed in triplicate and repeated $3times.
B7-1 transfection. HeLa cells were transfected with pcDNA3.1-
C-(k)DYK (NM_009855,ORF Sequence; GenScript HK Limited,
Hong Kong, China) plasmids using Lipofectamine 2000 according to
the supplier’s instructions (Invitrogen, Carlsbad, CA).
Cell immunoﬂuorescence studies. Primary cultures of podo-
cytes and differentiated podocytes were ﬁxed in 4% para-
formaldehyde for 20 minutes, permeabilized in phosphate-buffered
saline containing 0.2% Triton X-100, and then incubated with anti-
Nestin (Rat-401, Developmental Studies Hybridoma Bank), anti-
Nephrin (Progen Biotechnik), anti-Podocin (Sigma Aldrich), and
the 3 different anti-B7-1 (H-208, rabbit from Santa Cruz Biotech-
nology Inc.; 2A2, mouse from Abcam; AF140, goat from R&D
Systems Europe) antibodies. The primary antibodies were revealed
with the appropriate Alexa 488-, 555-, or 647-conjugated secondary
antibodies (Molecular Probes). Immunoﬂuorescence staining was
visualized using a Zeiss LSM 700 confocal microscope.
Real-time reverse transcriptasepolymerase chain reaction. B7-1
mRNA was detected in podocytes by real-time reverse transcriptase
polymerase chain reaction using an ABI PRISM 7700 Sequence
Detection system (Applied Biosystems, Foster City, CA). The primers
(Eurogentec, Liège, Belgium) used were as follows: B7-1 forward
50-TGTATGCCCAGGAAACAGGT-30 and reverse 50-AGCCCGAT-
CACCAC-TGATTA-30, podocin forward 50-GCT-GTC-TGC-TAC-TAC-
CGC-AT-30 and reverse 50-CTC-TCC-ACT-TTG-ATG-CCC-CA-30,
IL-6 forward 50-CCA-GAG-TCC-TTC-AGA-GAG-ATA-CA-30 and
reverse 50-CCT-TCT-GTG-ACT-CCA-GCT-TAT-C-30 and IL-1b for-
ward 50-TCA-TTG-TGG-CTG-TGG-AGA-AG-30 and reverse 50-GCC-
TGT-AGT-GCA-GTT-GTC-TAA-30.
RPL13 and Hprt were used as a normalization control.
Western blot
Western blots were performed as previously described.19 Brieﬂy,
protein extracts from podocytes were resolved by sodium
dodecylsulfate–polyacrylamide gel electrophoresis before being
transferred onto the appropriate membranes and incubated with the
3 different anti-B7-1 (H-208, rabbit from Santa Cruz Biotechnology;
2A2, mouse from Abcam; AF140, goat from R&D Systems Europe),
anti-Podocin (Sigma Aldrich); and anti-b actin (Sigma Aldrich)
antibodies, followed by the appropriate peroxidase-conjugated sec-
ondary antibodies. Chemiluminescence was acquired using a Fusion
FX7 camera (Vilber Lourmat, Eberhardzell, Germany), and densi-
tometry was performed using ImageJ software (National Institutes of
Health, Bethesda, MD).ction), in NZB/W F1 mice (age 46 weeks), and in mice 2 months after
lar basement membrane in kidneys of vehicle- or LPS-treated mice 1
) and 3 different anti-B7-1 antibodies (red, 2A2: ab86473 from Abcam;
logy Inc.) in the parafﬁn-embedded kidneys of all models of podocyte
(red, AF140: from R&D Systems) in the frozen sections of kidney of all
by a Tukey-Kramer test; all models versus sham: *** P < 0.001. DAPI,
1043
bas i c re sea r ch E Baye et al.: Podocyte injury and B7-1 expressionData analysis and statistics
The data are expressed as the means  SEM. Differences between the
experimental groups were evaluated using analyses of variance fol-
lowed by the Tukey-Kramer test when signiﬁcant (P < 0.05). Sta-
tistical analyses were performed using GraphPad Prism Software
(San Diego, CA).
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